

## Early and locally advanced breast cancer: diagnosis and management

### Review questions

*NICE guideline tbc*

*Review questions*

*November 2017*

*Draft for Consultation*

*Evidence reviews were developed by  
National Guideline Alliance hosted by the  
Royal College of Obstetricians and  
Gynaecologists*



## **Disclaimer**

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

## **Copyright**

© National Institute for Health and Care Excellence, 2016. All rights reserved. Subject to Notice of rights.

ISBN:

## **Contents**

<b>Review questions .....</b>	<b>5</b>
-------------------------------	----------

## Review questions

Review questions
Do tumour-free tissue margins wider than 0 mm reduce local recurrence for people with invasive breast cancer and/or ductal carcinoma in situ (DCIS) treated with breast conserving surgery?
Is there a subgroup of people who do not need axillary treatment when the axilla has been found to contain metastatic disease?
What are the best strategies to prevent lymphoedema following axillary intervention?
Is there a benefit of progesterone receptor (PR) testing for adjuvant chemotherapy planning?
What predictive prognostic tools, excluding gene profiling tests, should be used for determining adjuvant systemic therapy?
What is the optimal duration of adjuvant endocrine therapy for people with oestrogen-receptor positive breast cancer?
What is the effectiveness of ovarian suppression in addition to endocrine therapy in pre-menopausal women with oestrogen-positive breast cancer?
What is the role of chemoprevention in women following initial treatment for ductal carcinoma in situ (DCIS)?
Which people with early and locally advanced breast cancer would benefit from the addition of taxanes to anthracycline- based adjuvant chemotherapy?
Which people with T1N0 human epidermal growth receptor 2 (HER2)-positive breast cancers benefit from adjuvant trastuzumab in combination with chemotherapy?
What are the indications for using adjuvant bisphosphonates in people with early and locally advanced breast cancer?
What radiotherapy techniques are effective for excluding the heart from the radiation field without compromising coverage of the whole breast target volume for people with early or locally advanced breast cancer?
Is there a subgroup of people with early invasive breast cancer who do not need breast radiotherapy after breast-conserving surgery?
Is there a subgroup of women with early invasive breast cancer for whom partial breast radiotherapy is an equally effective alternative to whole breast radiotherapy after breast-conserving surgery?
What are the indications for radiotherapy to internal mammary nodes?
What are the indications for post mastectomy radiotherapy for people with early and locally advanced breast cancer?
Should the potential need for radiotherapy preclude immediate breast reconstruction?
What is the effectiveness of neoadjuvant chemotherapy?
Is there a benefit for neoadjuvant endocrine therapy for people with early and locally advanced breast cancer?
What are the indications for post mastectomy radiotherapy following neoadjuvant systemic therapy?
Do people with triple negative or BRCA germ line mutation with early and locally advanced breast cancer benefit from the addition of a platinum to anthracycline ( $\pm$ taxanes) based neo-adjuvant chemotherapy?
What lifestyle changes improve breast cancer-specific outcomes in people treated for early and locally advanced breast cancer?